6NMQ | pdb_00006nmq

Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase 2 (PHD2) in Complex with the Carboxamide Analog JNJ43058171


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.58 Å
  • R-Value Free: 
    0.260 (Depositor), 0.278 (DCC) 
  • R-Value Work: 
    0.222 (Depositor) 
  • R-Value Observed: 
    0.224 (Depositor) 

wwPDB Validation 3D Report Full Report

Validation slider image for 6NMQ

Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history

Literature

Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2.

Bembenek, S.D.Venkatesan, H.Peltier, H.M.Rosen, M.D.Barrett, T.D.Kanelakis, K.C.Palomino, H.L.Brondstetter, T.I.Mirzadegan, T.Rabinowitz, M.H.

(2019) ACS Omega 4: 6703-6708

  • DOI: https://doi.org/10.1021/acsomega.9b00199
  • Primary Citation Related Structures: 
    6NMQ

  • PubMed Abstract: 

    A combination of structure-based drug design and medicinal chemistry efforts led us from benzimidazole-2-carboxamide with modestly active hypoxia-inducible factor prolyl hydroxylase 2 inhibition to certain benzimidazole-2-pyrazole carboxylic acids that were more potent as well as orally efficacious stimulators of erythropoietin secretion in our in vivo mouse model. To better understand the structure-activity relationship, it was necessary to account for (i) the complexation of the ligand with the active site Fe 2+ , (ii) the strain incurred by the ligand upon binding, and (iii) certain key water interactions identified by a crystal structure analysis. With this more complete computational model, we arrived at an overarching paradigm that accounted for the potency differences between benzimidazole-2-carboxamide and benzimidazole-2-pyrazole carboxylic acid enzyme inhibitors. Moreover, the computational paradigm allowed us to anticipate that the bioisostere replacement strategy (amide → pyrazole), which had shown success in the benzimidazole series, was not generally applicable to other series. This illustrates that to fully reconcile the important ligand-active site interactions for certain targets, one often needs to move beyond traditional structure-based drug design (such as crystallographic analysis, docking, etc.) and appeal to a higher level of computational theory.


  • Organizational Affiliation
    • Discovery Sciences and Cardiovascular Metabolic Therapeutic Area, Janssen Research & Development, San Diego, California 92121, United States.

Macromolecule Content 

  • Total Structure Weight: 24.23 kDa 
  • Atom Count: 1,702 
  • Modeled Residue Count: 187 
  • Deposited Residue Count: 213 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Egl nine homolog 1213Homo sapiensMutation(s): 0 
Gene Names: EGLN1C1orf12PNAS-118PNAS-137
EC: 1.14.11.29
UniProt & NIH Common Fund Data Resources
Find proteins for Q9GZT9 (Homo sapiens)
Explore Q9GZT9 
Go to UniProtKB:  Q9GZT9
PHAROS:  Q9GZT9
GTEx:  ENSG00000135766 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9GZT9
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
KU1

Query on KU1



Download:Ideal Coordinates CCD File
C [auth A]N-(4-oxo-1,4-dihydrocinnoline-3-carbonyl)glycine
C11 H9 N3 O4
WSQQFPKJCSYPLX-UHFFFAOYSA-N
FE2

Query on FE2



Download:Ideal Coordinates CCD File
B [auth A]FE (II) ION
Fe
CWYNVVGOOAEACU-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.58 Å
  • R-Value Free:  0.260 (Depositor), 0.278 (DCC) 
  • R-Value Work:  0.222 (Depositor) 
  • R-Value Observed: 0.224 (Depositor) 
Space Group: H 3 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 91.1α = 90
b = 91.1β = 90
c = 169.33γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
HKL-2000data reduction
Cootmodel building
MOLREPphasing
HKL-2000data scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2019-04-24
    Type: Initial release
  • Version 1.1: 2019-06-26
    Changes: Data collection, Database references
  • Version 1.2: 2024-03-13
    Changes: Data collection, Database references